B. Tromp

发表

A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors

J. Machiels, J. Tabernero, R. Kurzrock, 2014, Clinical Cancer Research.

A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors

A. Tolcher, K. Papadopoulos, A. Patnaik, 2013, Cancer Chemotherapy and Pharmacology.

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.

M. Beksac, M. Dimopoulos, Kihyun Kim, 2021, The New England journal of medicine.

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.

H. Goldschmidt, Shaji K. Kumar, T. Plesner, 2021, The Lancet. Oncology.

A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease

R. Kurzrock, H. van de Velde, P. Voorhees, 2015, Oncotarget.

Siltuximab Treatment Increases Hemoglobin (Hb) Levels: Preliminary Results From a Prospective Phase 1 Study In Refractory Solid Tumors

R. Kurzrock, M. Cornfeld, Steven J. Cohen, 2010 .

Outcomes By Cardiac Stage in Newly Diagnosed AL Amyloidosis: Results from Andromeda

M. Maurer, A. Dispenzieri, E. Kastritis, 2020 .

Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study

T. Plesner, H. Nahi, A. Oriol, 2023, Leukemia & lymphoma.

Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA

S. Iida, T. Ikezoe, Kihyun Kim, 2023, Annals of Hematology.

Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma

G. Cook, S. Basu, R. Schots, 2022, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Phase I/II, two-part, open-label, multiple-dose, dose-escalation study of siltuximab in patients with solid tumors

J. Machiels, R. Kurzrock, L. Dirix, 2012 .

Efficacy of Daratumumab, Lenalidomide, and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma and Impaired Renal Function from the Phase 3 Maia Study Based on Lenalidomide Starting Dose

H. Goldschmidt, Shaji K. Kumar, T. Plesner, 2021, Blood.

Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study

D. Chauveau, Kihyun Kim, E. Kastritis, 2020 .

Subcutaneous Daratumumab (DARA SC) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Asian Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Subgroup Analysis from the Phase 3 Andromeda Study

S. Iida, T. Ikezoe, Kihyun Kim, 2020 .